Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia

Bone Marrow Transplantation

Volumn 20, Issue 11, 1997, Pages 915-920

  Pawlowska, A B ^a   Blazar, B R ^a   Angelucci, E ^b   Baronciani, D ^b   Shu, X O ^c   Bostrom, B ^d  

^a University of Minnesota   (United States)

^b Div Ematologica Ctro Trapianto M   (Italy)

^c UNIVERSITY OF MINNESOTA   (United States)

^d CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

Author keywords

Bone marrow transplantation; Busulfan; Pharmacokinetics; Thalassemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FERRITIN; SULFONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASIA; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CHILD; CHIMERA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; FERRITIN BLOOD LEVEL; HUMAN; INTERSTITIAL PNEUMONIA; LIVER BIOPSY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEIZURE; TREATMENT OUTCOME; VEIN OCCLUSION;

EID: 0030727574     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701001     Document Type: Article

References (26)

1. Ehrsson H, Hassan M. Determination of busulfan in plasma by gas chromatography with selected ion monitoring. J Pharm Sci 1983; 72: 1203-1205.
2. Grochow LB, Krivit W, Withley CD, Blazar B. Busulfan disposition in children. Blood 1990; 75: 1723-1727.
3. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
4. Vassal G, Gouyette A, Hartman O et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386-390.
5. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
6. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. New Engl J Med 1990; 332: 417-421.
7. Lucarelli G, Clift RA, Galimberti M et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87: 2082-2088.
8. Muretto P, Del Fiasco S, Angelluci E et al. Bone marrow transplantation in thalassemia: modification of hepatic iron overload and associated lesions after long-term engrafting. Liver 1994; 14: 14-24.
9. Henner WD, Furlong EA, Flahetry MD, Shea TC. Measurement of busulfan by high-performance liquid chromatography. J Chromatogr 1987; 416: 426-432.
10. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
11. Andreani M, Manna M, Lucarelli G et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494-3499.
12. Glucksberg H, Storb R, Fefer A et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donor. Transplantation 1974; 18: 295-304.
13. Ehrsson H, Hassan M, Ehrnebo M, Beran M. Busulfan kinetics. Clin Pharmacol Ther 1983; 34: 86-89.
14. Yeager AM, Wagner JE Jr, Graham ML et al. Optimization of busulfan dose in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
15. Hassan M, Ehrsson H, Smedmyr B et al. Cerebrospinal fluid and plasma concentration of busulfan during high dose therapy. Bone Marrow Transplant 1989; 4: 113-114.
16. Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 1990; 27: 226-228.
17. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulfan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-134.
18. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-2479.
19. Locasciulli A, Bacigalupo A, Alberti A et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989; 48: 68-72.
20. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimen. Semin Oncol 1993; 20 (Suppl. 4): 18-25.
21. Schuler U, Schroer S, Kuhnle A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759-765.
22. Shaw PJ, Scharping CE, Brian RJ Earl JW. Busulfan pharmacokinetics utilizing a single daily dose regiment in children with acute leukemia. Blood 1994; 84: 2357-2362.
23. Demirer T, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996; 17: 341-346.
24. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
25. Van der Jagt RHC, Appelbaum FR, Petersen FB et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest chemotherapy. Bone Marrow Transplant 1991; 8: 211-215.
26. Regazzi MB, Locatelli F, Buggia I et al. Disposition of high dose busulfan in pediatric patients undergoing bone marrow transplant. Clin Pharmacol Ther 1993; 54: 45-52.